Cancer clinical trials in the region Provence-Alpes-Côte d'Azur
432 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Breast cancer
Stomach and esophageal cancer
#NCT06324357
#2023-509566-38-00
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Other
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Boehringer Ingelheim
Phase 1 / Phase 2
Colon cancer
Rectal cancer
#NCT06324357
#2023-509566-38-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Boehringer Ingelheim
Phase 1 / Phase 2
Breast cancer
Stomach and esophageal cancer
#NCT06324357
#2023-509566-38-00
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Boehringer Ingelheim
Phase 1 / Phase 2
Chronic myeloid leukemia (CML)
#NCT04835584
LMC en phase accélérée (Phase 2 Bras C)
Required disease stage
Accelerated phase
Required genetic anomalies
BCR-ABL
Ph+ (Philadelphia chromosome positive)
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded genetic anomalies
T315I
TP53
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Kartos Therapeutics
Phase 1 / Phase 2
Chronic myeloid leukemia (CML)
#NCT04835584
LMC Phase Chronique (phase 1b et phase 2 Bras A et B)
Required disease stage
Chronic phase
Required genetic anomalies
BCR-ABL
Ph+ (Philadelphia chromosome positive)
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded genetic anomalies
T315I
TP53
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Kartos Therapeutics
Phase 1 / Phase 2
Acute leukemia
#NCT04256317
Phase 1 et 2 : Thérapie combinée
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy
Targeted therapy
Car-T
3 recruiting sites
Taiho Oncology
Phase 1 / Phase 2
Chronic myeloid leukemia (CML)
#NCT06163430
#2023-507677-18-00
Required disease stage
Chronic phase
Required genetic anomalies
BCR-ABL
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded previous treatments
Systemic Treatment-Naive
6 recruiting sites
Terns, Inc.
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 2 - Cohorte 6
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ALK
BRAF
EGFR
HER2
KRAS G12C
MET
NTRK-1/2/3
RET
ROS-1
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 1 (Escalade de dose)
Required histologic types
SCLC (Small Cell Lung Cancer)
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 2 - Cohorte 7
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE